中国科学院机构知识库网格
Chinese Academy of Sciences Institutional Repositories Grid
Research Advances on Circumventing Tumor Multidrug Resistance

文献类型:期刊论文

作者Maio Zehong; Ding Jian
刊名Chinese Journal of Cancer
出版日期2003
卷号22期号:8页码:886-892
关键词Multidrug resistance (MDR) Antitumor agents P-glycoprotein (P-gp) Ceramide
ISSN号1000-467X
其他题名抗肿瘤多药耐的研究进展
文献子类Review
英文摘要Tumor multidrug-resistant(MDR) reverters inhibit the function of drug transporters and thus reverse MDR. In contrast, anti-MDR agents circumvent tumor MDR by directly inhibiting or killing MDR tumor. In recent years, the development of novel anti-MDR agents has become a major focus of research. This review summarized the advances in MDR mechanisms concentrating on the relationships between P-glycoprotein and apoptotic regulation and between ceramide signal system and MDR. With this understanding, the authors classified anti-MDR agents for the first time as agents which are structurally modified from MDR-related drugs, disrupt MDR mechanisms, induce caspase-independent apoptosis, interfere with ceramide metabolism, and are mechanism-unknown, Meanwhile, their mechanisms and major features of actions were also discussed.
WOS研究方向Oncology (provided by Clarivate Analytics)
语种中文
CSCD记录号CSCD:1247268
源URL[http://119.78.100.183/handle/2S10ELR8/268464]  
专题药理学第一研究室
作者单位Division of Anti-tumor Pharmacology, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Shanghai Institute of Materia Medica, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai 201203, China.
推荐引用方式
GB/T 7714
Maio Zehong,Ding Jian. Research Advances on Circumventing Tumor Multidrug Resistance[J]. Chinese Journal of Cancer,2003,22(8):886-892.
APA Maio Zehong,&Ding Jian.(2003).Research Advances on Circumventing Tumor Multidrug Resistance.Chinese Journal of Cancer,22(8),886-892.
MLA Maio Zehong,et al."Research Advances on Circumventing Tumor Multidrug Resistance".Chinese Journal of Cancer 22.8(2003):886-892.

入库方式: OAI收割

来源:上海药物研究所

浏览0
下载0
收藏0
其他版本

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。